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Abstract
Background: The interstitium, situated between the blood and lymph vessels and the cells, consists of a solid or
matrix phase and a fluid phase, together constituting the tissue microenvironment. Here we focus on the
interstitial fluid phase of tumors, i.e., the fluid bathing the tumor and stromal cells. Novel knowledge on this
compartment may provide important insight into how tumors develop and how they respond to therapy.
Results: We discuss available techniques for interstitial fluid isolation and implications of recent findings with
respect to transcapillary fluid balance and uptake of macromolecular therapeutic agents. By the development of
new methods it is emerging that local gradients exist in signaling substances from neoplastic tissue to plasma.
Such gradients may provide new insight into the biology of tumors and mechanistic aspects linked to therapy. The
emergence of sensitive proteomic technologies has made the interstitial fluid compartment in general and that of
tumors in particular a highly valuable source for tissue-specific proteins that may serve as biomarker candidates.
Potential biomarkers will appear locally at high concentrations in the tissue of interest and will eventually appear in
the plasma, where they are diluted.
Conclusions: Access to fluid that reliably reflects the local microenvironment enables us to identify substances that
can be used in early detection and monitoring of disease.
Introduction
The interstitial space consists of connective and sup-
porting tissues of the body and is located outside the
blood and lymphatic vessels and parenchymal cells.
Essentially the interstitium can be divided into two com-
partments: the interstitial fluid and the structural mole-
cules of the interstitial or the extracellular matrix
(ECM). In the present review we focus on the interstitial
fluid phase, which contains an array of regulatory mole-
cules defining the physical and biochemical microenvir-
onment of cells. All organs have an interstitium,
although at a variable amount. The structure and com-
position of the interstitium differs considerably depend-
ing on the mother organ. Interstitial water with its
solutes, the interstitial fluid volume, serves as a trans-
port medium for nutrients and waste products between
cells and capillary blood and also harbors various signal-
ing substances that are either produced locally or
brought to the organ by the circulation.
Recently there has been a renewed interest in the
tumor microenvironment because of its role in tumor
growth and metastasis. The tumor microenvironment
can be defined as the insoluble elements of the ECM,
the stroma with its cellular elements such as fibroblasts
and immune cells and the fluid phase of dissolved sub-
stances. Traditionally the focus has been on the stroma
and the cellular elements of the tumor, whereas here we
focus on the fluid phase that may be thought of as a
“misconsidered component of the internal milieu of a
solid tumor” [1].
We discuss recent data on the isolation of interstitial
fluid and what can be learned from analyses of such
fluid regarding local production of signaling substances
and potential biomarkers as well as the level of intersti-
tial fluid colloid osmotic pressure, one of the determi-
nants of transcapillary fluid exchange. For a broader
description of the latter topic, the reader is referred to
reviews on transcapillary fluid exchange and interstitial
fluid volume regulation [2-9]. The composition and
structure of the interstitium has been the topic of
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topic is not discussed here.
The tumor interstitium
Although the tumor interstitium consists of the same
components as the interstitia of normal tissues, i.e., an
extracellular or interstitial matrix composed of solid ele-
ments constituting the framework of the tumor and a
fluid phase constituting the interstitial fluid; it has its
special features that are discussed briefly here. Before
we turn to the interstitial/extracellular fluid phase, we
summarize some common features of the ECM or solid
phase in tumors compared to normal interstitium, as
schematized in Figure 1. We do not discuss the proper-
ties of the tumor stroma, which has been the topic of
several extensive recent reviews [16-22]. As stated by
Kalluri and Zeisberg [18], there is considerable interest
in understanding the differences between a normal
stroma and a reactive tumor stroma. The normal
stroma in most organs contains a minimal number of
fibroblasts, whereas a reactive stroma is associated with
an increased number of fibroblasts, enhanced capillary
density, and type I collagen and fibrin deposition. A key
factor in the formation of the reactive stroma is the vas-
cular endothelial growth factor (VEGF) [23], either
released by the cancer cells themselves or by fibroblasts,
or inflammatory cells [24]. Increased levels of VEGF
results in a high microvascular permeability that causes
extravasation of plasma proteins such as fibrin, which in
turn attract an influx of fibroblasts, inflammatory cells
and endothelial cells [25,26]. The resulting reaction has
similarities to wound healing where the cells produce
an ECM rich in fibronectin and type I collagen and
thus influence the composition of the stroma but also
contribute to the process of initiating tumor angiogen-
esis [26,27]. Compared with non-neoplastic tissue, the
tumor stroma contains increased amounts of collagens,
proteoglycans and glycosaminoglycans, especially hyalur-
onan and chrondroitin sulfate, [e.g., [28-30]], as
reviewed in [31]. These cellular responses are parallel to
wound healing; the difference is that the generation of
tumor stroma may be considered dysregulated wound
healing [27].
Tumor interstitial fluid
The abnormal interstitium representing the microenvir-
onment of the tumor cells has puzzled researchers for
many years and continues to do so. Recently, an
increased interest in the tumor microenvironment and
its influence on cancer progression has turned attention
toward this compartment (e.g., [18,19,22,32-34]). One
may therefore envisage that access to tumor interstitial
fluid (TIF), i.e., the fluid bathing the tumor and stroma
cells, is of considerable importance to understand how
tumors develop and progress. The properties of the
tumor interstitium, e.g., the high vascularity and cellular-
ity, represent major challenges when trying to gain
access to the TIF.
Methods of fluid isolation
To quantify one of the determinants of the transcapil-
lary fluid balance, the interstitial fluid protein concentra-
tion, and thus interstitial fluid colloid osmotic pressure
as well as the tissue fluid concentration of signaling sub-
stances and molecules that may reflect local cellular
processes, it is imperative to have the appropriate meth-
odologies that provide reliable and representative native
interstitial fluid.
In tumors, there is no uniform agreement as to which
method to use to isolate TIF. As discussed above, lymph
has been generally accepted as a measure of interstitial
fluid [3]. Although many studies have shown that lymph
vessels are present in tumor tissue (for review, see
[35-38]), these vessels appear to be nonfunctional, i.e.,
not draining any fluid, at least in central tumor areas
[37,39]. In addition, tumor lymphatics may not be can-
nulated, making lymph sampling inapplicable in this tis-
sue, showing the need for alternative methods in
tumors. We therefore discuss the available methods and
their strengths and weaknesses from a tumor point of
view (summarized in Table 1) before we turn to a dis-
cussion on recent data on composition of the interstitial
fluid.
Glass capillaries
The glass capillary method for TIF isolation was
described by Sylven and Bois [40]. They noted that the
tumor periphery was rich in edema-like interstitial fluid,
and isolated such fluid by inserting capillaries, 0.1-0.6
mm in diameter, into pouches made by blunt dissection
in and along the periphery of the tumor or into sec-
tioned tumor surface. The sampling procedure did not
allow exact localization of the site of origin of the fluid,
and Sylven and Bois acknowledged that it was possible
that normal tissue fluid could also be included. Another
obvious problem is an inherent tendency for cellular
and vascular leakage that is likely to occur during sam-
pling. The isolated fluid contained very high levels of
intracellular enzymes, which indicates that the fluid iso-
lated this way is a mixture of interstitial and intracellular
fluid.
Implantable chambers
Much of our knowledge on TIF derives from experi-
ments performed by Gullino et al. [41] in rats bearing
various tumors using implantable chambers. The cham-
bers were either inserted into a growing tumor or
enclosed in it by allowing a tumor to grow around the
chamber. The chamber was separated from tumor tissue
by a porous membrane. Fluid draining into the chamber
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Figure 1 The interstitial space in normal tissue and tumors. Top: The interstitium (i.e., loose connective tissue outside the blood and lymph
vessels) in normal tissue consists of interstitial fluid and a solid extracellular matrix (ECM) again consisting of collagen fibers, glycosaminoglycans,
i.e., hyaluronan and proteoglycans and fibroblasts. Notice the lymphatic vessel that is filled and drains filtered fluid and immune cells. Bottom:
The interstitium in tumors is more disorganized than in normal tissue, and tumors have a so-called reactive stroma. A normal stroma in most
organs contains a minimal number of fibroblasts, whereas reactive stroma is associated with an increased number of fibroblasts, enhanced
capillary density and irregular blood vessels that have high microvascular permeability, again resulting in extravasation of plasma proteins such
as fibrin, which in turn attract an influx of fibroblasts, inflammatory cells and endothelial cells. Compared with non-neoplastic tissue, the tumor
stroma contains increased amounts of collagen having variable fiber size, proteoglycans and glycosaminoglycans, especially hyaluronan and
chrondroitin sulfate. Tumors have lymphatics, at least in the periphery, but lymphatics may be compressed (pictured as a flattened lymph vessel)
and thus nonfunctional.
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After a period, necrosis developed and some hemor-
rhages appeared, but there was a definite interval when
the chamber was enclosed by neoplastic cells and a low
amount of necrosis that was used for fluid sampling. A
main advantage with this approach is that fluid can be
harvested for longer periods, e.g., to follow effects of
therapy. Many of the potential problems with the
method have been discussed by Jain [42]. One obvious
issue is the inflammatory reaction and subsequent scar-
ring that is induced by chamber insertion.
Implanted wicks
As for skin and muscle (for review, see [3]), wicks have
been implanted in various types of solid tumors in mice
to isolate interstitial fluid. Stohrer et al. [43] implanted
saline-soaked wicks directly into established tumors
(termed acute wicks) or simultaneously with tumor
implantation (termed chronic wicks) and characterized
the isolated fluid. In addition to evaluating the effect of
acute and chronic insertion, they evaluated the effect of
both implantation time and tumor type. They concluded
that acute wick implantationr e q u i r e sal o n gt i m ef o r
equilibration (i.e., >120 min) and that chronic wicks
should be preferred to avoid bleeding and cellular
damage. Furthermore, as pointed out by Stohrer et al.,
cellular proteins deriving from necrotic cells or cells dis-
rupted during wick removal may enter the wick fluid
and cause a higher protein concentration (and higher
colloid osmotic pressure). As a result, the protein distri-
bution pattern will deviate from that of undisturbed
tumor interstitial fluid, i.e., mainly proteins with lower
molecular weight (MW) than albumin, e.g., as observed
in skeletal muscle [44].
Microdialysis
The microdialysis technique, based on diffusion of ana-
lytes across a semipermeable membrane, has been
applied extensively to study TIF (for reviews, see
[45-52]). With this technique it is possible to sample
endogenous and exogenous substances from the extra-
cellular space, mainly small molecular species. At pre-
sent, there has been an increased interest in using the
technique in pharmacokinetic and pharmacodynamic
s t u d i e s[ 4 8 , 4 9 , 5 3 ] ,b u ti th a sa l s ob e e na p p l i e dt os t u d y
peptides and proteins dissolved in the interstitial fluid
(for recent reviews see, e.g., [54,55]). In such a context
the major problems with the method is incomplete
recovery of substances and also the potential inflamma-
tory reactions resulting from insertion of the probe, and
as pointed out by Clough [55], it is therefore unlikely
that the dialysate reflects a representative concentration
of the interstitial fluid.
Capillary ultrafiltration
Ultrafiltration has traditionally been used for separation
or purification of chemicals, but this technique has also
been applied to sample tissue fluid by implanting capil-
lary ultrafiltration probes in vivo (reviewed in [56]).
With this method fluid is sampled using negative pres-
sure as a driving force, and the restriction induced by
the semipermeable membrane affects the size of mole-
cules that are allowed in the ultrafiltrate sample. As for
Table 1 Methods for tumor interstitial fluid isolation
Method How performed What was sampled Advantages Disadvantages Remarks References
Glass
capillaries
Insertion by blunt
dissection in vivo
Fluid from tumor
periphery or sectioned
surface
In vivo native fluid Bleeding and
inflammation,
cellular disruption
High level of
intracellular enzymes
in isolated fluid
[40]
Implantable
chambers
Chronically implanted Fluid draining from
central part of tumor
In vivo native fluid,
continuous and
repeated sampling
Inflammation in
early phases, scar
formation
Requires chronic
restraining of animal
[41]
Implanted
wicks
Implanted acutely or
chronically
Fluid absorbed into
wicks during
implantation
In vivo, native fluid Bleeding and
inflammation,
cellular disruption
Chronic implantation
more representative
than acute
[43]
Microdialysis Insertion of
semipermeable
membrane
Substances diffusing
across membrane
In vivo continuous and
repeated sampling
Inflammation,
incomplete
recovery, dilute
fluid
Recovery especially
low for
macromolecules
Reviewed
in [45]
Capillary
ultrafiltration
Negative pressure
applied to
semipermeable
membrane
Substances transported
by bulk flow across
membrane
In vivo continuous and
repeated sampling
Inflammation,
incomplete
recovery
Recovery especially
low for
macromolecules
[60]
Tissue
centrifugation
Exposure of excised
tissue to increased G-
force
Fluid from tumor
periphery or bone
marrow
Native fluid Ex vivo single
samples
Composition validated
by extracellular tracers
[61,77]
Tissue elution Elution of minced
tissue
Substances dissolved
in elution buffer
Technically easy Ex vivo single
samples, dilute fluid
Contamination by
intracellular proteins
likely
[67]
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to 100%, whereas in vitro recovery for albumin has been
found to be 74% [57], suggesting that ultrafiltration can
be used for interstitial fluid sampling. The technique has
also been used for collection of tissue fluid from skin
[58,59] and fibrosarcomas in mice [60] using mem-
branes with MW cutoff of 400 kDa to allow for sam-
pling of proteins secreted to the interstitial fluid
("secretome”). The protein concentration in the sampled
fluid is, however, very low compared to that obtained
with other methods (1/300 or lower for skin or <1/1000
for tumors; see section “Composition of tumor intersti-
tial fluid” and Table 2). These results suggest that pro-
teins are sieved off at the capillary membrane, in the
tissue or at the tissue-membrane interface during ultra-
filtration, and accordingly that ultrafiltration fluid does
not represent interstitial fluid composition.
Tissue centrifugation
Recently, we described a centrifugation method for
tumor interstitial fluid isolation [61] based on experi-
ments having shown that tissue fluid could be isolated
from cornea [62] and tail tendon [63,64] by exposing tis-
sue to increased G-force. Crucial questions are whether
the isolated fluid represents undisturbed interstitial fluid
and whether there is contamination with cell fluid. Cell
compression during centrifugation may lead to extrusion
of cellular fluid, resulting in the isolation of a mixture of
interstitial and cytoplasmic fluid. This question has been
addressed in a study in rats bearing chemically induced
mammary carcinomas using the extracellular tracer
51Cr-ethylenediaminetetraacetic acid (EDTA) as a probe
to show possible ‘contamination’ of cellular fluid. Addi-
tion of tumor cell fluid to the centrifuged volume
should thus show up as a reduced
51Cr-EDTA concen-
tration in the centrifugate relative to plasma (Figure 2).
The finding of a ratio in peripheral tumor not
significantly different from 1.0 for g ≤ 424 suggested no
dilution of extracellular fluid, indicating that the isolated
fluid is representative for TIF provided a G-force in this
range. The procedure was later found suitable for inter-
stitial fluid isolation in other tumor models [65,66].
Tissue elution
Recently, in a search for novel biomarkers, Celis et al.
[67] proposed that tissue elution would be a suitable
method to isolate tumor interstitial fluid. They used
clean, fresh biopsies obtained from women with invasive
breast cancer. Biopsies were cut into small pieces (1-3
mm
3) that were washed carefully and placed in tubes
containing phosphate-buffered saline. After incubation
or elution for 1 h followed by centrifugation, the super-
natant was collected and named tumor interstitial fluid.
Later, they used the same elution method to isolate fat
interstitial fluid [68]. In the tumor study, they found
that the TIF contained some major serum proteins as
might be expected, but that its overall protein profile
was remarkably different from that of serum. Clearly,
sectioning of cell-rich tumors into small pieces results
in sectioning of an unknown fraction of cells and addi-
tion of cell fluid to the eluate.
Composition of tumor interstitial fluid
The functional importance of the TIF has been
acknowledged in earlier studies by Jain [42], and it is
therefore surprising that there has been little focus on
the TIF compartment. We here briefly discuss old data
and focus on new developments. In doing so, we discuss
t h ed a t ai nl i g h to ft h el i m i t a t i o n si n h e r e n tf o rt h e
methods used for fluid isolation.
Gullino et al. [41,69] were the first to measure the
concentration of various low molecular weight solutes,
and in Table 2 we have summarized data on some char-
acteristics of TIF. When compared to plasma and
Table 2 Composition of interstitial fluid in tumors
Tumor type Host Protein, mg/ml COP, mm Hg pH Lactic acid,
mg/l
Reference
TIF Subcutis Plasma TIF Subcutis Plasma TIF Plasma
(arterial)
TIF Plasma
Carcinoma (Walker 256) Rat 32 ±
1
41 ± 2 48 ± 1 7.044
±0.044
7.313 ±
0.041
16.1 ±
1.1
9.5 ±
0.9
[41,95]
Mammary carcinoma Mouse 54 55 - 60 [40]
Carcinoma (Walker 256) Rat 6.98 ±
0.13
15 15 [70]
Colon adenocarcinoma
(LS174T)
Mouse 16.7 ±
3.0
[43]
Small cell lung carcinoma
(54A)
21.1 ±
2.8
8.2 ±2.3 20.0 ±
1.6
Mammary carcinoma
(chemically induced)
Rat 44.7 54.9 16.6 ±
1.0
13.8 ±1.0 20.5
±0.8
[61]
COP: Colloid osmotic pressure, TIF: Tumor interstitial fluid. Empty cells in table: Value not determined
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Page 5 of 11subcutaneous interstitial fluid, TIF has high H
+,C O 2,
and lactic acid and low glucose and O2, probably a
result of tumor metabolism [42]. Of note, the pH of the
TIF was 0.2-0.4 units lower and fell even more with
increasing tumor size [70], the PCO2 was 16-39 mmHg
higher, and the concentration of bicarbonate was 4-6
mmol/l higher when compared to afferent plasma.
There has, however, been some development during
recent years regarding the macromolecular composition
of TIF that is of importance for our understanding of
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Figure 2 Determination of possible contamination of interstitial fluid. (A) A tracer that does not pass intracellularly is equilibrated in the
extracellular fluid phase. (B) If undiluted interstitial fluid (IF) is isolated, the concentration in IF and plasma (P) will be equal, i.e., IF/P = 1.0. If,
however, intracellular fluid (with dissolved proteins) not containing tracer is added to the interstitial fluid during the isolation process (e.g.,
centrifugation), the IF will become diluted and as a consequence IF/P <1.0. (C) Tissue-to-plasma distribution ratios (IF/P) of the extracellular tracer
51Cr-ethylenediaminetetraacetic acid (EDTA) as a function of G-force for interstitial fluid isolated by centrifugation from intact tumor and skin
(means ± SE). For g < 424, the IF/P ratio was not significantly different from 1.0, suggesting negligible dilution and thus contamination of IF. An
IF/P <1.0 for g > 424 (*P < 0.05 for tumor as well as skin) suggested contamination of IF with intracellular water and proteins (Data in Figure 2C
modified from [61]).
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fluid exchange is determined in tumors as in normal tis-
sue by the Staling principle, i.e., by the net filtration
pressure being the difference between the hydrostatic
and colloid osmotic pressure acting across the capillary
wall.
Whereas there are numerous studies where tumor
interstitial fluid pressure has been measured and found
to be elevated (for review, see [71]); in two studies only
has colloid osmotic pressure (COP) been measured in
TIF (Table 2). Stohrer et al. [43] determined COPTIF in
four different human tumor xenografts in mice using
implanted wicks. Using chronic wicks (see section
“Implanted wicks” above), they found a generally higher
pressure in TIF than in subcutaneous tissue. In three of
the four tumor types, COP in TIF was not significantly
different from plasma (or actually tended to be higher),
whereas in a colon adenocarcinoma (LS174T), the COP
was 82% of that in plasma and the COP in subcutaneous
interstitial fluid was 41% of the plasma value. In a recent
study, we measured COP in TIF isolated by centrifuga-
tion of excised chemically induced mammary carcinomas
[61], and we found that the TIF/plasma COP ratio was
0.75-0.79, again significantly higher than the correspond-
ing subcutaneous ratio of 0.60 and close to the value for
LS174T colon adenocarcinomas. The high COP observed
in these two studies corresponds well to the high protein
concentration relative to plasma of 0.8-1.0 found by Syl-
ven et al. [40], although the data from Gullino et al. [41]
suggest lower COP in TIF in their model. Thus, although
some caution must be expressed regarding potential con-
tamination of intracellular and plasma proteins discussed
for capillary and wick sampling above (see sections
“Glass capillaries” and “Implanted wicks”), all data sug-
gest that there is a high colloid osmotic pressure and pro-
tein concentration in TIF.
The observed protein distribution pattern in intersti-
tial fluid may also be of interest since this pattern may
have implications for the interpretation of potential bio-
marker candidates that are discussed in the following
section. Gullino et al. [41] subjected TIF to paper elec-
trophoresis and found an albumin-to-globulin ratio of
TIF similar to that of afferent blood. A somewhat differ-
ent picture was observed by Stohrer et al. [43] after
separation by sodium dodecyl sulfate-gel electrophoresis.
For proteins 25-75 kDa, the concentration in TIF and
plasma was not significantly different, whereas for pro-
teins with MW <25 kDa the concentration in TIF was
on average 2.4 times higher than in plasma. As noted by
Stohrer et al. [43], these smaller proteins can be break-
down products from necrotic areas and tumor-derived
cell proteins as well as cellular enzymes [40]. We com-
pared the gel chromatography elution patterns for TIF
with that of plasma [61], and whereas the patterns for
albumin (MW ~69 kDa) and larger molecules were
similar, there was a larger fraction of molecules eluting
in the lower MW region, in agreement with data from
Stohrer et al. [43] discussed above. Clearly there is a
need for identification of proteins in TIF to better char-
acterize the microenvironment and thus to understand
local signaling events as well as to search for potential
biomarkers.
Biological implications of recent studies on
interstitial fluid
Adding to the value of identifying “new” substances in
the interstitium, e.g., using proteomic approaches, it is
also important to quantify known bioactive compounds
in the interstitial fluid. Numerous growth factors and
cytokines are associated with and sequestered in the
ECM (e.g., [72-75]). Posttranslational modifications may
occur in this compartment, and to be able to under-
stand biological processes, it may be of importance to
monitor biomolecules in the compartment where they
are biologically active, i.e., in the interstitial fluid rather
than at a gene level as elegantly shown by Garvin and
Dabrosin [76]. In a mammary cancer model they
demonstrated that although estradiol and the antiandro-
gen tamoxifen increased mRNA and intracellular VEGF
protein, the secreted VEGF to the extracellular phase,
and thereby angiogenesis, was decreased by the latter
substance. Such observations highlight the importance
of studying signaling substances in the interstitial fluid
phase of the target organ and also show the importance
of quantification of substances in the microenvironment.
Having demonstrated that interstitial fluid could be
isolated from bone marrow in rats and humans by cen-
trifugation [77], we then isolated bone marrow intersti-
tial fluid (BMIF) from patients with acute myeloid
leukemia (AML) at the time of diagnosis and 2-4 weeks
after the start of induction therapy [78]. We found that
AML-derived BMIF, but not plasma, repressed hemato-
poietic cell growth and that this effect was lost by suc-
cessful induction treatment (Figure 3). Tumor necrosis
factor a and adiponectin concentrations were higher in
BMIF showing local production, and our experiments
[78] suggested that these two cytokines had a mechanis-
tic role in the disease process. Whereas plasma levels of
these cytokines were unaffected by therapy, the levels
fell significantly in BMIF in patients entering remission,
showing that quantification of substances in interstitial
fluid may give important information on disease pro-
gression. Two recent studies [79,80] have shown the
therapeutic importance of targeting syndecan-1 heparan
sulfate proteoglycan in the local microenvironment and
not in plasma in hematological cancers.
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Page 7 of 11Figure 3 Signaling substances in bone marrow interstitial fluid (BMIF) in leukemia. (A) Growth of normal bone marrow progenitor cells
(CD34 cells) added BMIF from patients with acute myeloid leukemia (AML) before and after induction chemotherapy. A marked increase in
colony numbers (*P < 0.05) was noted upon this initial treatment in 7 of 10 patients with AML entering complete remission. BMIF from the
remaining three AML patients that only entered partial remission yielded similar colony numbers before and after induction chemotherapy.
Colony formation in the presence of normal BMIF is shown for comparison. (B) Tumor necrosis factor (TNF)-a concentrations in plasma and BMIF
before and after induction chemotherapy in 7 of 10 patients with AML entering complete remission. This treatment resulted in a substantial fall
in TNF-a concentration (*P < 0.05) in the BMIF, but not in plasma. Normal plasma and BMIF values are shown for comparison. Individual values
are shown. Horizontal lines refer to means. Modified from [78].
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identification of biomarkers
The advances of mass spectrometry techniques com-
bined with bioinformatics allow detection, identification
and quantification of numerous peptides and proteins in
biological samples (e.g. [81-86]). The emergence of these
technologies and the possibility of isolating fluid deriv-
ing from a specific tissue environment offer new ave-
nues for detection of tissue-specific biomarkers, notably
for tumors. Biomarkers may be defined as molecular
indicators whose presence or metabolism correlates with
important disease-related processes and/or disease out-
comes [87] and may be important for detection of risk,
early disease and response to treatment. An attractive
source for biomarkers is fluids that can be sampled non-
invasively, and in addition to plasma/serum, such studies
have been performed on urine, cerebrospinal fluid,
bronchoalveolar lavage fluid, synovial fluid, nipple aspi-
rate fluid, tear fluid and amnion fluid (reviewed in [88]).
One general problem is the complexity of the fluids
sampled and the dynamic range in the proteins sampled.
This applies especially to plasma/serum, and therefore
techniques have emerged to enrich and study subpro-
teomes to reduce the complexity and to be able to
detect low abundant proteins [89,90]. Still, even when
studying subproteomes of plasma/serum, the potential
biomarkers deriving from a local disease process such as
solid cancer will be diluted in a substantial volume,
which represents the sum of the cellular processes of
the body. The chances of detecting disease-specific bio-
markers will therefore be greater if the search is per-
formed closer to the disease process, i.e., in the tissue
microenvironment. Tumor cells are known to release
specific substances that disrupt the tissue and elicit local
responses, and it is likely that candidates can be found
locally in the tumor cell secretome, i.e., specific sub-
stances secreted by tumor cells [91-94]. For this purpose
it is necessary to have a technique that reflects the true
interstitial fluid.
Summary and perspectives
Although substantial interest has been devoted to the
ECM, the same cannot be said about the interstitial or
extracellular fluid phase. Here we have focused on the
interstitial fluid phase of tumors, and although the
importance of this type of study in normal as well as
neoplastic tissues was emphasized more than 20 years
ago [42], there have been surprisingly few studies on
this topic in tumors since the classical studies by Gul-
lino et al. [41] more than 40 years ago. More recently it
has been established that the colloid osmotic pressure
gradient across the tumor microvascular wall is low,
consistent with the findings of increased permeability of
tumor vessels. With the development of new methods,
local cytokine gradients between tumor and plasma have
been demonstrated that may result in new insight in
tumor biology. The emergence of proteomic technolo-
gies makes interstitial fluid in general, but particularly
that from tumors, a very valuable source for biomarkers.
As we have discussed, a major challenge in this quest is
to ascertain that the source fluid derives from the inter-
stitial fluid, but if we can, the potential of such an
approach is substantial.
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